Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1806310
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Taysha Gene Therapies filed an 8-K on Oct 9, 2025, with SEC. Standard update.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on October 9, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Dallas, Texas, operates in the biological products sector.
Why It Matters
This filing indicates Taysha Gene Therapies is providing updates on significant events and financial information to the SEC, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not contain specific material events that would inherently increase risk.
Key Numbers
- 2025-10-09 — Filing Date (Date of the 8-K filing)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- October 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Address of Principal Executive Offices
- 001-39536 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 9, 2025.
What is Taysha Gene Therapies, Inc.'s industry?
Taysha Gene Therapies, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, SIC code 2836.
Where are Taysha Gene Therapies, Inc.'s principal executive offices located?
The principal executive offices of Taysha Gene Therapies, Inc. are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the company's fiscal year end?
The company's fiscal year ends on December 31 (1231).
What is the Commission File Number for Taysha Gene Therapies, Inc.?
The Commission File Number for Taysha Gene Therapies, Inc. is 001-39536.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-09 08:24:24
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d949053d8k.htm (8-K) — 25KB
- d949053dex991.htm (EX-99.1) — 20KB
- 0001193125-25-235212.txt ( ) — 167KB
- tsha-20251009.xsd (EX-101.SCH) — 3KB
- tsha-20251009_lab.xml (EX-101.LAB) — 18KB
- tsha-20251009_pre.xml (EX-101.PRE) — 11KB
- d949053d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 9, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. By: /s/ Kamran Alam Date: October 9, 2025 Kamran Alam Chief Financial Officer